The MarketReader Minute
đź’Š Biotech Slumps Despite FDA Policy Shift; argenx Rises on Phase 3 Win; Moderna & BridgeBio Slide | Biotech Sector Insights
(IBB) fell, The FDA announced daily reporting on drug-related adverse events, a move aimed at modernizing surveillance. Still, key holdings like (REGN) and (MRNA) weighed heavily, offsetting positive headlines such as Amgen’s FDA approval.